The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
What an absolutely horrific update. £25m loss. And the worst part is we're due another one before the court case next June. Could well be 20p by then, and on the outside chance Nova win the case, the market knows it won't be long till the rest of the cash is pi55ed away so at best it'll go back to a quid. Shocking incompetence.
They'd be better off sacking all the board, staff, assets like buildings and IPR, and just spread what little cash is left across savings accounts paying 3.5%+. Can be run by an accountant, and then just pay dividends of 3.4%
I see that the majority of applications so far have been rejected for the trial. I presume these are from people self referring for that last bit of hope rather than referred from a clinician who has matched up trial requirements versus the patients best interests. Quite a sad thought to start the day
Presention notes leaked online.
Ow do. Ah'm Alan. Thank theur for comin t' presention, wi've summa' we 'ope tha'il enjoy. I got face on cos ot share price, burrit bloody werks. I'll hand over t' Fi, ah'm off for breadcake, take it away duck.
Not surprised tbh.
If you saw two people, one puts their entire £100m fortune on red on a roulette wheel for a single spin, the other just spins the roulette wheel but only makes minimum wage, who is the safer option?
Some big director buys would be nice, but it seems they'd rather play it safe too given they could be out of work in 18 months.
Board can't spend it, would be seen as deliberate deprivation of funds, they'll have been told they cannot spend anything above usual day to day operations, certainly no more acquisitions or share buy backs.
Just a case of waiting will June 24, and make a decision whether to stick more money in to average down enough to see some profit if the court case is favourable and counter case is also upheld, balanced with chucking money down the drain it they lose or have to settle at detrimental terms.
If avacta moves to nasdaq, what happens to our shares? Do they just transfer over, or are they sold at market price before being made available for purchase again? Is there potential CGT liability if outside SIPP or ISA?
Basically, can us shareholders be shafted if they move?
In my mind given nothing quantified so far, therapeutic dose = amount of dox you'd expect in a tumour if given a standard session of dox based Chemo. So, it's already great news, as we're not seeing the associated cardiotoxicity.
I think what Al is looking for now, is order of magnitudes greater presence of dox in the tumour, to show an unprecedented amount of tumour killing chemicals can be made safe. Will absolutely blow the doors off the thing, this can be the only reason for further DE, to show there's nothing else on the planet that can do what pre cision can do. He's showed it works even better than in the lab, now we're at the show boating stage, and he's decided the financial hit and 6-12 month delay is worth it in the long run. I can't argue with that.
All these concerned posters are hilarious, they're absolutely ****ed if they have a short in place.
I think it's a combination of that the market works on facts, we're pretty damn confident that 1b is a formality, proving efficacy, Mr market wants this clinically proven, 2nd part is phase 2 funding. We're hopeful it'll be through licencing 3996 or other candidate from the precision platform, and imo its the most likely, but Mr market according to statistics of thinks a further fund raise might occur.
The difference between Mr Market and the majority of LTH is we have done the research to base our investment decisions and 1a has shown its better than we imagined, they rely on a computer to do it for them.
Either way, I hope its still this price come early Feb when my next pension payment goes in, I feel like I'm robbing someone. Whatever happens, and however they decide to fund things over next few years, this is only going one way. Roll on science day, maybe then we'll see some (inter) national news interest.
Other drugs could be radionuclides used in nuclear medicine. They're delivered intravenously but go all around the body, and then the scans show where masses shouldn't be. Makes your mouth taste like you're licking an iron bar. You then have another drug that makes the body expel it by p*ssing constantly for about an hour, making your kidneys hurt. Comes with a small risk being radioactive. Something similar could be applied here, so the radioactive substances concentrate in the tumour, meaning a much smaller amount is required, making it less risky to the patient, and no need to p*ss in to a bottle sat in the passenger seat on the way home, which is the main benefit imo
@Dickz, based on commercial court time availability when the last RNS was posted about counter suing, at the time for complex court cases (ie, greater than 2 days availability) the earliest available dates were late March 23 (2 days) to July 23 (for week long cases). Obv one party could cave in and settle before then, but in my mind these are the two dates I've had in my calendar since that RNS.
Theres been more avacta trades than GSK ones this morning. Novacyt took 3 months to go from £2.50 to £12, hemo did 25% after a decent RNS and then went up another 125% over the following week.
Today its the 10% traders taking their profit who pay zero attention to RNSs or pipelines and they'll move on to someone else.